Entrada Therapeutics Inc (TRDA)

Currency in USD
13.99
-0.04(-0.29%)
Closed·
13.990.00(0.00%)
·
TRDA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
13.7414.24
52 wk Range
4.9314.49
Key Statistics
Prev. Close
14.03
Open
13.99
Day's Range
13.74-14.24
52 wk Range
4.93-14.49
Volume
79.16K
Average Vol. (3m)
215.28K
1-Year Change
77.9898%
Book Value / Share
8.54
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TRDA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
21.40
Upside
+52.97%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Entrada Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Strong Buy

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Compare TRDA to Peers and Sector

Metrics to compare
TRDA
Peers
Sector
Relationship
P/E Ratio
−3.5x−7.6x−0.5x
PEG Ratio
0.01−0.020.00
Price / Book
1.6x3.6x2.6x
Price / LTM Sales
19.8x17.5x3.2x
Upside (Analyst Target)
43.0%53.2%45.7%
Fair Value Upside
Unlock−13.5%4.8%Unlock

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 21.40
(+52.97% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Oppenheimer
Buy23.00+64.40%21.00MaintainApr 06, 2026
Cantor Fitzgerald
Buy---New CoverageApr 01, 2026
TD Cowen
Buy---MaintainMar 23, 2026
Guggenheim
Buy20.00+42.96%-New CoverageFeb 10, 2026
Oppenheimer
Buy21.00+50.11%-New CoverageJan 28, 2026

Earnings

Latest Release
Feb 26, 2026
EPS / Forecast
-0.94 / -0.98
Revenue / Forecast
1.3M / 5.81M
EPS Revisions
Last 90 days

TRDA Income Statement

People Also Watch

21.68
AMPH
+1.40%
146.74
INSM
-4.34%
5.57
SPT
+6.30%
131.44
NBIX
+0.48%
824.01
LITE
-3.37%

FAQ

What Is the Entrada Therapeutics (TRDA) Stock Price Today?

The Entrada Therapeutics stock price today is 13.99 USD.

What Stock Exchange Does Entrada Therapeutics Trade On?

Entrada Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Entrada Therapeutics?

The stock symbol for Entrada Therapeutics is "TRDA."

What Is the Entrada Therapeutics Market Cap?

As of today, Entrada Therapeutics market cap is 505.08M USD.

What Is Entrada Therapeutics's Earnings Per Share (TTM)?

The Entrada Therapeutics EPS (TTM) is -3.47.

When Is the Next Entrada Therapeutics Earnings Date?

Entrada Therapeutics will release its next earnings report on May 07, 2026.

From a Technical Analysis Perspective, Is TRDA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Entrada Therapeutics Stock Split?

Entrada Therapeutics has split 0 times.

How Many Employees Does Entrada Therapeutics Have?

Entrada Therapeutics has 152 employees.

What is the current trading status of Entrada Therapeutics (TRDA)?

As of Apr 16, 2026, Entrada Therapeutics (TRDA) is trading at a price of 13.99 USD, with a previous close of 14.03 USD. The stock has fluctuated within a day range of 13.74 USD to 14.24 USD, while its 52-week range spans from 4.93 USD to 14.49 USD.

What Is Entrada Therapeutics (TRDA) Price Target According to Analysts?

The average 12-month price target for Entrada Therapeutics is 21.40 USD, with a high estimate of 25 USD and a low estimate of 19 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +52.97% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.